Our top stories from February 2021, including: The effectiveness of mobile stroke units, evidence for a new transient ischaemic attack (TIA) scoring system, endovascular thrombectomy (EVT) during the COVID-19 period, and commentary on complete versus near-complete reperfusion for acute ischaemic stroke.
In a study published in The Journal of the American Medical Association (JAMA), researchers have found that stroke patients in Berlin for whom STEMOs (Stroke-Einsatz-Mobile) were dispatched were more likely to survive without long-term disability.
A study published in Neurorehabilitation and Neural Repair finds that the capacity of the human brain to recover and rewire itself peaks around two weeks after an ischaemic stroke, and diminishes over time.
CereVasc has announced the treatment of the first patient in a study of its eShunt System, an investigational device intended to treat communicating hydrocephalus (CH).
Stryker announced a new partnership with Brainomix that provides an option for European customers to purchase Brainomix’s e-Stroke software.
Ching-Jen Chen discusses his recent publication in the BMJ entitled, “Is a picture-perfect thrombectomy necessary in acute ischaemic stroke?”
Medtronic today announced expansion of the limited site release of its recently acquired radial artery access portfolio from privately-held Rist Neurovascular, following first-in-patient procedure. This portfolio includes the Rist 079 radial access guide catheter and Rist radial access selective catheter.
A new study published in the British Medical Journal (BMJ), has concluded that the Canadian transient ischaemic attack (TIA) score identifies the risk of patients with transient ischaemic attack (or mini-stroke) for a subsequent stroke or carotid artery revascularisation within seven days.
Biomodex has announced its partnership with two of the top medical centres in France and a health system in the USA to develop Evias Plus, a training solution for treatment of ischaemic stroke.
ShiraTronics has announced that it has been granted a breakthrough device designation by the Center of Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) for its neurostimulation therapy targeting chronic migraine sufferers.
A study recently published in the BMJ reports no observed delay in the treatment of patients with intracranial occlusion with endovascular thrombectomy (EVT) during the COVID-19 era when compared with the pre-COVID era.